InnerMedical Announces Close Of ￥100M Series C Financing Round

(VCBeat) Apr. 30, 2021 -- Shenzhen Yingmeida Medical Technology Co., Ltd. ("InnerMedical") has recently raised RMB100 million in Series C financing. This funding round is led by Zhongke Kechuang, with participation from new and existing investors such as EFUNG Investment, SZHTI Group, Sangel Venture, Guiyang Venture Capital and Jida Asset. This round of funds will be mainly used for the development of products under R&D and the marketing and commercialization of existing products.

InnerMedical was founded in 2015. After 6 years of development, it has become an innovative high-tech medical company covering R&D, production and sales. With the development idea of platform technology, InnerMedical focuses on optical, ultrasonic and energy technology, developing minimally invasive instruments of digestive and cardiac diseases. Its core products include imaging equipment and consumables such as ultrasonic endoscopes, angiography systems and electronic endoscopes, as well as high-end active therapeutic instruments for interventional surgery.

With the aging of the population, cancer and cardiovascular and cerebrovascular diseases have become the deadliest diseases and health problems. In the corresponding diagnosis and treatment fields, there still needs a large number of innovative products to meet the clinical demands. InnerMedical develops innovative imaging equipment and high-end therapeutic instruments for major diseases such as cancers, and cardiovascular and cerebrovascular diseases. It is committed to providing complete solutions for minimally invasive devices for interventional surgery.

Zhongke Kechuang was established on July 15, 2009, under the guidance and support of Guangdong Provincial Party Committee and Guangdong Provincial Government, as the initiator and manager of Baiyun Equity Investment Fund, the first large record-based equity investment fund in Guangdong Province.

EFUNG Investment is one of China's earliest institutions investing in professional biomedical industries. Over a decade of years, EFUNG Investment has been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices.